The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers

Laboratory findings, compassionate use of favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015 — a retrospective observational study

(2019) Romy Kerber et al.   JOURNAL OF INFECTIOUS DISEASES

QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient

(2017) Pierangelo Chinello et al.   PLoS Neglected Tropical Diseases

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

(2017) Thi Huyen Tram Nguyen et al.   PLoS Neglected Tropical Diseases

Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days

(2016) Boubacar Diallo et al.   CLINICAL INFECTIOUS DISEASES

Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation

(2016) Tal Lorberbaum et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

(2016) Daouda Sissoko et al.   PLOS MEDICINE

Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults

(2015) Yuji Kumagai et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS